We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

Download Mobile App





Next Generation Sequencing Testing Protocol for SARS-CoV-2 Can Process Tens of Thousands of Samples in Less Than 48 Hours

By LabMedica International staff writers
Posted on 26 May 2021
Print article
Image: Next Generation Sequencing Testing Protocol for SARS-CoV-2 Can Process Tens of Thousands of Samples in Less Than 48 Hours (Photo courtesy of Peter Duchek)
Image: Next Generation Sequencing Testing Protocol for SARS-CoV-2 Can Process Tens of Thousands of Samples in Less Than 48 Hours (Photo courtesy of Peter Duchek)
A new testing protocol for SARS-CoV-2 can process tens of thousands of samples in less than 48 hours and could also be adapted to many more pathogens.

The method, called SARSeq, has been developed by researchers at the Vienna BioCenter (Vienna, Austria) by combining their expertise in genomics, RNA biochemistry and data analysis.

Molecular tests that detect the presence of SARS-CoV-2 have become the best way to isolate positive cases and contain the spread of the virus. Several methods have come forward, some that detect viral proteins from nasopharyngeal swabs (such as antigen tests), and some that detect the presence of viral RNA from swabs, gargle samples, or saliva samples (such as reverse transcription and polymerase chain reaction tests, or RT-PCR).

Although antigen tests facilitate some logistical aspects of mass testing, their detection power is relatively weak – infected individuals carrying low amounts of virus remain undetected and can continue to infect other people. PCR tests, on the other hand, are more sensitive because they multiply fragments of the viral genome before scanning samples for the virus. However, they rely on the detection of fluorescent labels that tag viral sequences, which means that pooling samples coming from different people makes the process rather inefficient: if a pool tests positive, all the samples within the pool must be tested again individually to identify the source of the fluorescent signal. Too many machines needed, too expensive, too slow.

The new method developed by scientists at the Vienna BioCenter could enable large groups to be tested for SARS-CoV-2 with the same sensitivity as regular PCR tests. SARSeq, or ‘Saliva Analysis by RNA sequencing’, achieves high sensitivity, specificity, and the power to process up to 36,000 samples in less than 48 hours. The testing principle is conceptually simple: individual patient samples are collected into the wells of a testing plate - one well for each sample. Then, a fragment of viral RNA unique to SARS-CoV-2 - the nucleocapsid gene - is selectively converted to DNA and PCR-amplified in any well that contains it.

What distinguishes this first step to the usual PCR test is that each sample receives a unique set of short DNA sequences – or barcodes – that attach to the amplifying viral DNA. In a second amplification step, all the samples from one plate are pooled into one well, which receives a second set of unique DNA barcodes. The contents of multiple plates can be pooled once more, as the DNA molecules from each sample carry a unique combination of two sets of barcodes. This pooling and barcoding strategy makes SARSeq highly specific and scalable. Moreover, the NGS-based method allows to test several RNAs in parallel, including RNAs that control the sample quality or RNAs from other pathogens for differential diagnostics.

The testing procedure can run in parallel to existing diagnostics, while being independent of the bottlenecks in supply chains. Therefore, it does not compete with other testing methods for reagents or equipment. The principles behind SARSeq are simple and adaptable to any respiratory pathogen. As the world’s population skyrockets along with our proximity to animals, cutting-edge diagnostic methods like SARSeq will be crucial to prevent future diseases from spreading like wildfire.

“Amplifying the viral material from individual samples to a maximum homogenizes its quantity across positive samples, making SARSeq highly sensitive,” explained Luisa Cochella, group leader at the Research Institute of Molecular Pathology (IMP). “Within the thousands of samples that we could test simultaneously, some may contain up to 10 million times more coronavirus particles than others – if we pooled such samples before amplification, those with high amounts of viral material could mask other positive cases.”

“We combine the sensitivity of PCR with the high throughput of Next Generation Sequencing technology, or NGS, the same used to sequence the human genome. The NGS machine processes the pooled samples and tells us which samples contained any SARS-CoV-2 material. The barcodes allow us to distinguish each positive sample from the others, and trace it back to a patient,” added Ramesh Yelagandula, first author of the study.

Related Links:
Vienna BioCenter

New
Gold Supplier
SARS-CoV2 Antigen Rapid Test
SARS-CoV2 Antigen Rapid Test
New
Silver Supplier
Remote Lab Review Software
CellaVision Remote Review Software
New
Silver Supplier
COVID-19 IgM & IgG Quality Control
COVID-19 IgM & IgG Quality Control
New
Next-Generation Sequencing (NGS) Workstation
NGS STAR for COVID-19

Print article
BIOHIT  Healthcare OY

Channels

Industry

view channel
Image: Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device (Photo courtesy of Quidel Corporation)

Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device

Quidel Corporation (San Diego, CA, USA) has received an amended Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) allowing the company to market Sofia Q, its latest addition... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.